Literature DB >> 16164395

Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.

Nigel J Dagenais1, Fakhreddin Jamali.   

Abstract

Angiotensin II, the major effector molecule produced from the renin-angiotensin-aldosterone axis, is a vasoconstrictor contributing to hypertension. Evidence indicates, however, that angiotensin II also is a potent proinflammatory mediator with growth and remodeling effects. In vitro and in vivo studies have shown that angiotensin II blockade significantly reduces concentrations of proinflammatory mediators and oxidative stress products in numerous inflammatory models. Interruption of angiotensin II activity with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers has been beneficial for patients with inflammatory diseases. Much of this benefit occurs independent of the antihypertensive effect of angiotensin II interruption, suggesting a distinctive protective mechanism. Angiotensin II receptor blockers may represent a novel class of antiinflammatory drugs with indications far beyond cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16164395     DOI: 10.1592/phco.2005.25.9.1213

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  40 in total

1.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

2.  Acute adriamycin-induced cardiotoxicity is exacerbated by angiotension II.

Authors:  Eylem Taskin; Elvan Kunduz Kindap; Kalender Ozdogan; Mukerrem Betul Yerer Aycan; Nurcan Dursun
Journal:  Cytotechnology       Date:  2014-07-15       Impact factor: 2.058

3.  Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity.

Authors:  Forough Sanaee; John D Clements; Alistair W G Waugh; Richard N Fedorak; Richard Lewanczuk; Fakhreddin Jamali
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

Review 4.  Prevention of Stroke in Rheumatoid Arthritis.

Authors:  Alicia M Zha; Mario Di Napoli; Réza Behrouz
Journal:  Curr Neurol Neurosci Rep       Date:  2015-12       Impact factor: 5.081

5.  Inflammation alters angiotensin converting enzymes (ACE and ACE-2) balance in rat heart.

Authors:  Sherif Hanafy; Mahtab Tavasoli; Fakhreddin Jamali
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

6.  Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice.

Authors:  John J Byrnes; Stefan Gross; Courtney Ellard; Kelly Connolly; Stephen Donahue; Dominic Picarella
Journal:  Inflamm Res       Date:  2009-06-11       Impact factor: 4.575

7.  Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine.

Authors:  Roberto Fogari; Amedeo Mugellini; Paola Preti; Annalisa Zoppi; Giuseppe Derosa
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

8.  Effect of obesity on response to cardiovascular drugs in pediatric patients with renal disease.

Authors:  Sherif Hanafy; Maury Pinsk; Fakhreddin Jamali
Journal:  Pediatr Nephrol       Date:  2008-12-13       Impact factor: 3.714

9.  An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis.

Authors:  Olga I Santiago; Edelmarie Rivera; Leon Ferder; Caroline B Appleyard
Journal:  Regul Pept       Date:  2007-10-23

10.  Regulation of oxidative stress and cardioprotection in diabetes mellitus.

Authors:  Tetsuya Hayashi; Tatsuhiko Mori; Chika Yamashita; Masatoshi Miyamura
Journal:  Curr Cardiol Rev       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.